Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neurofibromatoses × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 13 Carcinoma, Renal Cell 12 Neoplasm Metastasis 7 Neoplasms 6 Carcinoma, Hepatocellular 5 Thyroid Neoplasms 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Medullary 4 Breast Neoplasms 4 Brain Neoplasms 4 Pancreatic Neoplasms 3 Neuroendocrine Tumors 3 Thyroid Cancer, Papillary 2 Small Cell Lung Carcinoma 2 Recurrence 2 Pain 2 Multiple Myeloma 2 Lung Neoplasms 2 Kidney Neoplasms 2 Glioma 2 Glioblastoma 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Astrocytoma 2 Adenoma, Islet Cell 2 Adenocarcinoma, Follicular 2 Adenocarcinoma 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1

Interventions

tipifarnib 1 nilotinib 1 mirdametinib 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Lidocaine 1 Imatinib Mesylate 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡